Feb 25, 2020 (KD Market Insights via COMTEX) -- Antihyperlipidemic Drugs Market by Drug Class (Statins, PCSK9 Inhibitors, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, and Combination): Global Opportunity Analysis and Industry Forecast, 2019-2026
The Global Antihyperlipidemic Drugs Market is estimated to grow at a CAGR of 7.5% during the forecast period 2019-2026. As per the analyst, the market was valued at $9,456 million in the year 2018, and is anticipated to reach $16,864 million by the end of the year 2026.
Antihyperlipidemic Drugs reduce lipid levels in the blood and help to lower the levels of low-density lipoprotein (LDL) cholesterol, triglyceride levels, and raise the high-density lipoprotein (HDL) cholesterol. Antihyperlipidemic agents help to prevent coronary heart disease by compressing both primary and secondary symptoms. Antihyperlipidemic drugs are segmented into niacin, ezetimibe, fibric acid derivatives, HMG-CoA reductase inhibitors and bile acid sequestrants.
No comments:
Post a Comment